BzODZ-EPyr is a synthetic cannabinoid with an indole base and has been marketed as a designer drug in Russia.
This compound functions as a CB1 receptor agonist, boasting a pKB value 7.2. Notably, it highlights that substituting the ketone in 3-carbonyl indoles with an oxadiazole spacer typically does not result in a loss of activity.
|Chemical and physical data|
|Molar mass||372.472 g·mol−1|
1. What is BzODZ-EPyr?
BzODZ-EPyr is a synthetic cannabinoid with an indole base. It has been sold as a designer drug, particularly in Russia.
2. How does BzODZ-EPyr affect the CB1 receptor?
BzODZ-EPyr functions as a CB1 receptor agonist, meaning it activates the CB1 receptors in the endocannabinoid system. This interaction can produce various physiological effects.
3. What is the significance of the pKB value of 7.2?
The pKB value of 7.2 indicates the potency and affinity of BzODZ-EPyr for the CB1 receptor. It reflects the strength of its binding and influence on this particular receptor.
4. Can you explain the use of an oxadiazole spacer in BzODZ-EPyr?
BzODZ-EPyr is unique in that it features an oxadiazole spacer. The presence of this spacer is notable because it generally does not lead to a loss of activity. In other words, it maintains its effectiveness as a synthetic cannabinoid.
5. Is BzODZ-EPyr legal and safe for use?
The legal status of BzODZ-EPyr can vary by region and country. Synthetic cannabinoids like BzODZ-EPyr can have unpredictable and potentially harmful effects. It’s essential to be aware of and adhere to local regulations.
6. What are the potential risks associated with BzODZ-EPyr use?
Using synthetic cannabinoids, including BzODZ-EPyr, can pose various risks, including potential health hazards, unknown long-term effects, and possible legal consequences. Users should exercise caution and stay informed about the latest developments.
7. Where can I find more information about BzODZ-EPyr?
For a deeper understanding of BzODZ-EPyr, consider referring to scientific literature, research studies, and relevant authorities. Staying informed about its chemical properties, effects, and legal status is crucial for those interested or concerned about this substance.
- In February 2016, Shevyrin V, Melkozerov V, Eltsov O, Shafran Y, and Morzherin Y made a groundbreaking discovery regarding the synthetic cannabinoid “3-benzyl-5-[1-(2-pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole.” This marked the first detection of this substance in the illicit market of new psychoactive substances. The findings were documented in “Forensic Science International,” Volume 259, spanning pages 95–100. To delve deeper into this discovery, you can refer to doi:10.1016/j.forsciint.2015.12.019. The PMID for this publication is 26771874.
- In March 2008, Moloney GP, Angus JA, Robertson AD, Stoermer MJ, Robinson M, Wright CE, and their team engaged in the synthesis and investigation of cannabinoid activity in “1-substituted-indole-3-oxadiazole derivatives.” Their work led to the identification of novel agonists for the CB1 receptor. This study was published in the “European Journal of Medicinal Chemistry,” Volume 43, Issue 3, spanning pages 513–539. For a more comprehensive understanding, refer to doi:10.1016/j.ejmech.2007.04.007. The PMID for this publication is 17582659.
- US Patent US 6930118, attributed to Moloney PG and Robertson AD, pertains to “3-Oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives.” This patent, issued in 2005, provides insights into the creation and potential applications of these derivatives. It was assigned to Amrad Operations Pty. Ltd. and serves as a significant resource for understanding the development of related compounds.